NOR-TEST is a multi-centre PROBE ( prospective randomised , open-label , blinded endpoint ) trial designed to establish superiority of tenecteplase 0.4 mg/kg ( single bolus ) as compared with alteplase 0.9 mg/kg ( 10 % bolus +90 % infusion/60minutes ) for consecutively admitted patients with acute ischaemic stroke eligible for thrombolytic therapy , i.e. patients a ) admitted < 4hours after symptoms onset ; b ) admitted < 4hours after awakening with stroke symptoms c ) receiving bridging therapy before embolectomy.Randomisation tenecteplase : alteplase is 1:1 .